[HTML][HTML] Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind …
N Nampota-Nkomba, OM Nyirenda… - The Lancet Global …, 2022 - thelancet.com
Background Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised …
N Nampota-Nkomba, OM Nyirenda… - The Lancet. Global …, 2022 - europepmc.org
Background Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised …
N Nampota-Nkomba, OM Nyirenda… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
[PDF][PDF] Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind …
N Nampota-Nkomba, OM Nyirenda, L Khonde… - 2022 - researchgate.net
Background Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
[HTML][HTML] Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind …
N Nampota-Nkomba, OM Nyirenda… - The Lancet. Global …, 2022 - ncbi.nlm.nih.gov
Background Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised …
N Nampota-Nkomba, OM Nyirenda… - The Lancet Global …, 2022 - discovery.ucl.ac.uk
BACKGROUND: Typhoid fever is a substantial public health problem in Africa, yet there are
few clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and …
few clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and …
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised …
N Nampota-Nkomba, OM Nyirenda, L Khonde… - 2022 - cabidigitallibrary.org
Background: Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
[HTML][HTML] Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind …
N Nampota-Nkomba, OM Nyirenda, L Khonde… - The Lancet Global …, 2022 - Elsevier
Background Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
[PDF][PDF] Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind …
N Nampota-Nkomba, OM Nyirenda, L Khonde… - 2022 - academia.edu
Background Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised …
N Nampota-Nkomba, OM Nyirenda… - The Lancet. Global …, 2022 - europepmc.org
Background Typhoid fever is a substantial public health problem in Africa, yet there are few
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …
clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of …